Diethyltryptamine

Diethyltryptamine
Clinical data
Other namesDET; N,N-Diethyltryptamine; N,N-DET; T-9; T9
Routes of
administration
Oral, inhalation (smoking), intramuscular, intravenous, subcutaneous
Drug classNon-selective serotonin receptor agonist; Serotonin 5-HT2A receptor agonist; Serotonergic psychedelic; Hallucinogen
ATC code
  • None
Legal status
Legal status
Pharmacokinetic data
MetabolismOxidative deamination (MAO-ATooltip Monoamine oxidase A), N-oxidation, N-dealkylation
Metabolites
Onset of action
Duration of action2–4 hours
Excretionurine
Identifiers
  • N,N-diethyl-2-(1H-indol-3-yl)ethan-2-amine
CAS Number
PubChem CID
DrugBank
ChemSpider
UNII
KEGG
ChEBI
ChEMBL
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC14H20N2
Molar mass216.328 g·mol−1
3D model (JSmol)
Melting point169 to 171 °C (336 to 340 °F)
  • CCN(CC)CCC1=CNC2=C1C=CC=C2
  • InChI=1S/C14H20N2/c1-3-16(4-2)10-9-12-11-15-14-8-6-5-7-13(12)14/h5-8,11,15H,3-4,9-10H2,1-2H3 Y
  • Key:LSSUMOWDTKZHHT-UHFFFAOYSA-N Y
  (verify)

Diethyltryptamine (DET), also known as N,N-diethyltryptamine or T-9, is a psychedelic drug of the tryptamine family closely related to dimethyltryptamine (DMT). It is taken orally, but can also be used by parenteral routes.

The drug acts as a non-selective serotonin receptor agonist, including of the serotonin 5-HT2A receptor among others. It has not been found to occur endogenously. DMT is a close structural homologue of DMT and dipropyltryptamine (DPT). Other analogues of DET include 4-HO-DET (ethocin), ethocybin (4-PO-DET), and 5-MeO-DET.

DET was first synthesized in 1956 by Stephen Szára and subsequently described in material published in 1957. More systematic studies were reported later by Szára and colleagues and independently by Böszörményi and colleagues.